Lomitapide

證據等級: L5

預測適應症: 10 個

Lomitapide: From Homozygous Familial Hypercholesterolemia to Hyperlipoproteinemia

One-Sentence Summary

Lomitapide is an oral microsomal triglyceride transfer protein (MTP) inhibitor with established approval in the US (2012) and EU (2013) for treating Homozygous Familial Hypercholesterolemia (HoFH), a rare genetic disorder causing severely elevated LDL cholesterol and premature cardiovascular disease. The TxGNN model predicts it may be effective for Hyperlipoproteinemia (rank 9, score 99.74%) — the broader disease category that encompasses HoFH — with 12 clinical trials and 19 publications currently supporting this direction. Notably, TxGNN's highest-ranked predictions (ranks 1–8 and 10) are all rare platelet disorders; these lack any established mechanistic or clinical connection to Lomitapide and are rated L5 / Hold pending further investigation.

Quick Overview

Item	Content
Original Indication	Homozygous Familial Hypercholesterolemia (HoFH) — approved in US/EU; no Italian marketing authorization on record
Predicted New Indication	Hyperlipoproteinemia (TxGNN rank 9)
TxGNN Prediction Score	99.74%
Evidence Level	L1
Italy Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Lomitapide inhibits microsomal triglyceride transfer protein (MTP), an enzyme in the hepatocyte endoplasmic reticulum that is essential for loading triglycerides onto apolipoprotein B (ApoB) to assemble VLDL particles. When MTP is blocked, VLDL secretion drops sharply, and circulating LDL-C and ApoB levels fall substantially — even in patients who lack functional LDL receptors. This receptor-independent mechanism is precisely what separates Lomitapide from statins and PCSK9 inhibitors.

Homozygous Familial Hypercholesterolemia is the most severe subtype of Hyperlipoproteinemia type IIa. Patients carry two defective LDLR alleles, making receptor-dependent therapies largely futile and leaving Lomitapide as one of the few agents capable of achieving clinically meaningful LDL-C reductions (typically 40–50%). HoFH is nosologically classified within Hyperlipoproteinemia, so TxGNN's rank 9 prediction is a direct mechanistic match — not speculative repurposing, but a model-confirmed validation of established clinical use within a broader disease taxonomy.

On TxGNN's top-ranked predictions (ranks 1–8 and 10): The highest-ranked novel predictions are eight rare platelet conditions (thrombocytopenia subtypes, Glanzmann thrombasthenia, pseudo-von Willebrand disease, dense granule disease, etc.). MTP inhibition operates exclusively in hepatic lipoprotein metabolism and has no established mechanistic bridge to platelet production, granule biology, or platelet receptor function. The repurposing rationales in the Evidence Pack confirm this absence of a pathophysiological link. These predictions most likely reflect knowledge-graph topological proximity in the TxGNN network rather than genuine therapeutic signal. All are rated L5 and are on Hold.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06832371	Observational	Active, Not Recruiting	73	Multicenter retrospective-prospective study evaluating the effect of Lomitapide on Major Adverse Cardiovascular Events (MACE) in HoFH patients — delivers real-world cardiovascular outcomes data
NCT00943306	Phase 3	Completed	19	Long-term open-label follow-on study of Lomitapide (MTP inhibitor) in HoFH; assessed continued LDL-C efficacy and safety over multi-year treatment
NCT00730236	Phase 3	Completed	29	Pivotal Phase 3 study of AEGR-733 (Lomitapide) in HoFH patients on current lipid-lowering therapy; evaluated LDL-C reduction and long-term safety — key registration trial
NCT02173158	Phase 3	Completed	9	Single-arm open-label multicenter study of Lomitapide specifically in Japanese HoFH patients; confirmed cross-ethnic efficacy and safety
NCT04681170	Phase 3	Completed	46	International multicenter Phase 3 study evaluating Lomitapide efficacy and long-term safety in pediatric HoFH patients on stable lipid-lowering therapy — supports age-range expansion
NCT02135705	Observational	Recruiting	300	LOWER Registry: global prospective cohort study monitoring long-term safety and effectiveness of Lomitapide across real-world clinical settings; ongoing through 2028
NCT00559962	Phase 2	Completed	260	Double-blind placebo-controlled RCT of low-dose MTP inhibitor ± atorvastatin/ezetimibe/fenofibrate; evaluated hepatic fat accumulation by MRI spectroscopy — largest Phase 2 cohort
NCT00690443	Phase 2	Completed	44	Randomized double-blind study of AEGR-733 + atorvastatin 20 mg vs. atorvastatin monotherapy in moderate hypercholesterolemia; primary endpoint: % LDL-C change at 8 weeks
NCT01556906	Phase 2	Completed	6	Open-label dose-escalation safety study of Lomitapide (BMS-201038) in HoFH; established the dose-response profile for LDL-C and VLDL-C reduction across four dose levels
NCT05611528	Phase 3	Completed	10	Open-label real-world study of evinacumab added on top of background LMT (including Lomitapide) in Canadian HoFH patients — provides combination therapy and competitive context

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39426393	2024	Phase 3 Study	The Lancet Diabetes & Endocrinology	APH-19 trial: Lomitapide significantly reduced LDL-C in pediatric HoFH patients on standard-of-care therapy — primary efficacy phase results
37130090	2023	Expert Consensus / Guidelines	European Heart Journal	2023 EAS Consensus update on HoFH: revised diagnostic criteria (LDL-C >10 mmol/L triggers HoFH workup), updated treatment algorithms including Lomitapide
35148370	2022	Systematic Evidence Review	European Journal of Preventive Cardiology	Comprehensive synthesis of Lomitapide efficacy and safety in HoFH; integrates clinical trial and real-world evidence
39751968	2025	Review	Current Atherosclerosis Reports	Latest review of novel HoFH pharmacotherapies; positions Lomitapide alongside evinacumab, inclisiran, and RNA-based agents in current treatment landscape
36152419	2022	Clinical Study	Atherosclerosis	Lomitapide efficacy and safety evaluated in Familial Chylomicronaemia Syndrome (FCS) — signals a potential label extension beyond HoFH to severe hypertriglyceridemia
31741187	2019	Mechanistic Review	Current Atherosclerosis Reports	In-depth mechanistic review of Lomitapide (MTP inhibition) and Mipomersen (ApoB100 antisense) as LDL-receptor-independent lipid-lowering strategies
33766264	2021	Expert Review	Journal of the American College of Cardiology	JACC Focus Seminar on emerging LDL-C lowering agents; contextualizes Lomitapide within inclisiran, bempedoic acid, and PCSK9i landscape
28598687	2017	Review	Expert Opinion on Pharmacotherapy	Comprehensive clinical review of Lomitapide: mechanism, Phase 3 evidence, safety profile, drug interactions, and place in HoFH therapy
25936301	2015	Review	Atherosclerosis Supplements	Comparison of Lomitapide and Mipomersen for HoFH patients who remain uncontrolled on maximal statin therapy plus apheresis
25053660	2014	Consensus Statement	European Heart Journal	EAS Consensus Panel foundational position paper on HoFH: clinical diagnosis, genetic heterogeneity, and treatment recommendations anchoring Lomitapide's role

Italy Market Information

Lomitapide is currently not registered in Italy. No marketing authorizations were identified in the regulatory database.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	No Italian authorizations on record

Lomitapide (brand name Lojuxta®) holds a valid EMA marketing authorization for HoFH in adult patients, which provides a direct regulatory basis for AIFA submission. Clinicians requiring access for eligible HoFH patients in Italy may explore compassionate use or the named-patient exemption framework (Legge 648/96) while formal authorization is pending.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Lomitapide carries robust L1 evidence — multiple completed Phase 3 trials, an ongoing global observational registry, and a valid EMA approval — firmly supporting its use in Homozygous Familial Hypercholesterolemia, the most severe subtype of Hyperlipoproteinemia. The TxGNN prediction for Hyperlipoproteinemia is mechanistically coherent and evidence-backed, making the decision to advance straightforward. The primary guardrail is the absence of Italian market authorization and the need for a formal hepatic risk management plan, both of which are addressable through established regulatory pathways.

To proceed, the following is needed:

Submit an AIFA marketing authorization application referencing the existing EMA approval for Lojuxta® (Lomitapide) for HoFH in adults
Extend the pediatric dossier to AIFA, citing the completed APH-19 trial (NCT04681170 / PMID 39426393), to support authorization in patients under 18
Establish a hepatic monitoring protocol (ALT/AST at baseline and at each dose escalation; hepatic steatosis imaging) equivalent to the EU Risk Management Plan
Develop a patient and prescriber education program on mandatory low-fat diet adherence to minimize gastrointestinal dose-limiting adverse effects
Investigate AIFA Legge 648/96 compassionate use for HoFH patients in urgent need while formal authorization is being processed
Commission a formal knowledge-graph audit to explain why TxGNN ranks platelet disorders (ranks 1–8 and 10) above the drug's approved indication — this topological artifact warrants model calibration before further interpretation of those predictions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.